logo
Plus   Neg
Share
Email

Waddell & Reed Financial CFO Daniel Connealy To Retire - Quick Facts

Waddell & Reed Financial Inc. (WDR) announced that Daniel Connealy, 67, Senior Vice President and Chief Financial Officer, will retire from the position of Chief Financial Officer upon the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2013.

The company said that Connealy intends to continue his employment with the company in a non-executive role through June 2014 to assist in the transition of his responsibilities.

Connealy joined the company in 2004, bringing with him the experience as a CFO in the investment management industry and a long career as a partner with PricewaterhouseCoopers LLP.

In addition, the company said that its board intends to appoint Brent Bloss, 44, to succeed Connealy as Chief Financial Officer. Bloss is currently Senior Vice President-Finance, Treasurer and Principal Accounting Officer and has served in various finance and accounting roles since joining the company in 2002. Prior to joining the company, Bloss served as Senior Audit Manager with KPMG LLP.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT